Arab Today, arab today eu puts conditions on deals involving novartis gsk
Last Updated : GMT 16:55:22
Arab Today, arab today
Arab Today, arab today

EU puts conditions on deals involving Novartis, GSK

Arab Today, arab today

Arab Today, arab today EU puts conditions on deals involving Novartis, GSK

The European Commission approved GSK
Brussels - AFP

The European Union on Wednesday approved mega deals involving drugmakers Novartis of Switzerland and GlaxoSmithKline of Britain, provided they sell off assets in the vaccines and consumer health businesses.
The European Commission, the EU's executive arm, approved GSK's acquisition of Novartis's global human vaccines business as well as a tie-up of their global consumer health business under GSK control, it said in a statement.
These were announced as part of a series of multi-billion euro pharmaceutical industry deals last April.
The commission had feared that the transactions, as initially planned, would undermine competition in vaccines against meningitis and diphtheria as well as in a range of consumer health products to stop smoking and to treat cold sores, cold and influenza.
To tackle the commission's concerns, GSK pledged to "grant a worldwide, exclusive, perpetual licence of GSK's Nimenrix vaccine for bacterial meningitis and divest GSK's Mencevax vaccine for bacterial meningitis worldwide," the commission said.
GSK also pledged to conclude supply, distribution and transfer agreements for Novartis's vaccines against diphtheria and tetanus, it said.
The commission also approved Novartis's plans to acquire part of GSK's oncology, or cancer treatment, business portfolio.
It said "the decision is conditional upon the divestment of two of Novartis's" treatments for skin cancer: LGX818 and MEK162.
"The Commission had concerns that the transaction would have reduced competition and innovation for these products," it said.
The purchase by Novartis of GSK's oncology business was for $16 billion (14.1 billion euros) in cash, including $1.5 billion that would depend on future performance.
GSK's purchase of Novartis's vaccines was for up to $7.1 billion, also in cash.

 

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

Arab Today, arab today eu puts conditions on deals involving novartis gsk Arab Today, arab today eu puts conditions on deals involving novartis gsk

 



Arab Today, arab today

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

Arab Today, arab today eu puts conditions on deals involving novartis gsk Arab Today, arab today eu puts conditions on deals involving novartis gsk

 



Arab Today, arab today Designer Rania Adel reveals her new collection

GMT 17:59 2017 Monday ,12 June

Designer Rania Adel reveals her new collection
Arab Today, arab today France defies terrorism through tourism

GMT 15:18 2017 Saturday ,20 May

France defies terrorism through tourism
Arab Today, arab today Mai Al-Jeddawi presents décor ideas for Ramadan
View News in Arabic - Business: أخبار الشركات
Arab Today, arab today
Arab Today, arab today
Arab Today, arab today
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube
arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday